Yoshiharu Asaoka

Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI.

Cell-surface Fcγ receptors mediate innate and adaptive immune responses. Human Fcγ receptor I (hFcγRI) binds IgGs with high affinity and is the only Fcγ receptor that can effectively capture monomeric IgGs. However, the molecular basis of hFcγRIs interaction with Fc has not been determined, limiting our understanding of this major immune receptor. Here we report the crystal structure of a complex between hFcγRI and human Fc, at 1.80 Å resolution, revealing an unique hydrophobic pocket at the surface of hFcγRI perfectly suited for residue Leu235 of Fc, which explains the high affinity of this complex. Structural, kinetic and thermodynamic data demonstrate that the binding mechanism is governed by a combination of non-covalent interactions, bridging water molecules and the dynamic features of Fc. In addition, the hinge region of hFcγRI-bound Fc adopts a straight conformation, potentially orienting the Fab moiety. These findings will stimulate the development of novel therapeutic strategies involving hFcγRI.

The binding of soluble recombinant human Fcγ receptor I for human immunoglobulin G is conferred by its first and second extracellular domains.

Human FcγRI is a high affinity receptor for the Fc portion of human immunoglobulin G (IgG), and has extracellular, transmembrane and cytoplasmic regions. The extracellular region of human FcγRI, which is the part that interacts with human IgG, is comprised of three immunoglobulin-like domains. Unlike low affinity Fcγ receptors (FcγRII and FcγRIII), FcγRI has a unique third extracellular domain (D3). This study investigated the contribution of D3 to the binding between recombinant human FcγRI (rhFcγRI) and human IgG. The three extracellular domains and the first and second extracellular domains of human FcγRI were expressed by Escherichia coli as rhFcγRI and rhFcγRI-D1D2, respectively. The binding specificity of rhFcγRI-D1D2 to human IgG subclasses was the same as that of rhFcγRI. From surface plasmon resonance analysis, the binding affinity of rhFcγRI-D1D2 for human IgG1/κ was high (the equilibrium dissociation constant: KD=8.04 × 10(-10)M), but slightly lower than that of rhFcγRI (KD=2.59 × 10(-10)M). While the association of rhFcγRI-D1D2 with human IgG1/κ was same as that of rhFcγRI, the dissociation of rhFcγRI-D1D2 was faster than that of rhFcγRI. From these results, D3 of rhFcγRI would not contribute directly to the binding specificity and association of rhFcγRI, but to the holding bound human IgG.

Engineering of recombinant human Fcγ receptor I by directed evolution

Human FcγRI is a high-affinity receptor for human IgG. On the basis of its binding activity, recombinant human FcγRI (rhFcγRI) has several possible applications, including as a therapeutic reagent to treat immune complex-mediated disease and as a ligand in affinity chromatography for purification of human IgG. As the stability and production rate of rhFcγRI are low, it would need to be engineered for use in such applications. In this study, we demonstrated engineering of rhFcγRI by directed evolution through random mutagenesis and integration of mutations. Engineered rhFcγRI was expressed by Escherichia coli. Screening identified 19 amino acid mutations contributing to the thermal stability and production rate of rhFcγRI. By integration of these mutations, engineered rhFcγRI containing all 19 amino acid mutations (enFcRd) was constructed and showed markedly enhanced thermal stability (transition midpoint temperature [Tm] = 65.6°C) and production rate (3.27 mg L-medium(-1) OD(600)(-1)) compared with wild-type rhFcγRI (Tm = 48.5°C; production rate, 0.07 mg L-medium(-1) OD(600)(-1)) without a change in the specificities of binding to human IgG subclasses. Moreover, the binding affinity of enFcRd for human IgG1/к (equilibrium dissociation constant [K(D)] = 0.80 × 10(-10) M) was higher than that of wild-type rhFcγRI (K(D) = 1.23 × 10(-10) M). Our study showed that substantial engineering of rhFcγRI is possible.

Efficient expression of recombinant soluble human FcγRI in mammalian cells and its characterization

The extracellular domain of human FcγRI which interacts with a human IgG was expressed as recombinant soluble human FcγRI (rshFcγRI) by Chinese hamster ovary (CHO) cell. Stable CHO cell clones with efficient expression of rshFcγRI were established based on a dihydrofolate reductase (DHFR)/methotrexate (MTX) gene-amplification system. The CHO clones efficiently produced rshFcγRI under high-density continuous culture in a bioreactor. After 53 days of culture, the number of cells had reached approximately 4 × 10⁶ cells/mL in the bioreactor and the average production of rshFcγRI had reached 7.4 mg L-medium⁻¹ day⁻¹. Secreted rshFcγRI was purified to a homogeneous state using cation exchange and affinity chromatographies. The binding affinities of rshFcγRI to human IgG subclasses were determined using surface plasmon resonance analysis. The binding affinities of rshFcγRI to human IgG1/κ and IgG3/κ were high (1.59 × 10⁻¹⁰ and 2.81 × 10⁻¹⁰ M, respectively), whereas that of rshFcγRI to human IgG4/κ was lower binding affinity (1.41 × 10⁻⁸ M). Binding to IgG2/κ was not detectable. Examination of circular dichroism spectra indicated that rshFcγRI was rich in β-structures and loop or turn structures, but there were few α-helices. These results may be valuable for further studies of the structure and function of human FcγRI.